Literature DB >> 21963303

Cytotoxic and antivascular 1-methyl-4-(3-fluoro-4-methoxyphenyl)-5-(halophenyl)-imidazoles.

Bernhard Biersack1, Yazh Muthukumar, Rainer Schobert, Florenz Sasse.   

Abstract

A series of 1-methyl-4,5-diphenylimidazoles 6 with various patterns of m-halogen substitution at the 5-phenyl ring were tested for cytotoxicity in cancer and nonmalignant cell lines and for their capacity to prevent tube formation in HUVEC cultures. Unlike the monofluoro and difluoro derivatives 6a and 6e, the monobromo and diiodo analogs 6c and 6h were strongly cytotoxic and inhibited the polymerization of tubulin and the tube formation by HUVEC. The dibromo derivative 6g displayed a unique selectivity for KB-3-1 cervix and PC-3 prostate cancer cells. It also inhibited the tube formation by HUVEC and the polymerization of tubulin which is indicative of its potential antiangiogenic activity in solid tumors.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963303     DOI: 10.1016/j.bmcl.2011.09.005

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  4,5-Diaryl imidazoles with hydroxamic acid appendages as anti-hepatoma agents.

Authors:  Pietro Di Fazio; Susanne Lingelbach; Rainer Schobert; Bernhard Biersack
Journal:  Invest New Drugs       Date:  2014-11-20       Impact factor: 3.850

2.  Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation.

Authors:  Katharina Mahal; Bernhard Biersack; Henrike Caysa; Rainer Schobert; Thomas Mueller
Journal:  Invest New Drugs       Date:  2015-02-14       Impact factor: 3.850

3.  Synthesis, biological evaluation, and modeling studies of 1,3-disubstituted cyclobutane-containing analogs of combretastatin A4.

Authors:  Andrii Malashchuk; Anton V Chernykh; Vasyl V Hurmach; Maxim O Platonov; Oleksandra Onopchenko; Sergey Zozulya; Constantin G Daniliuc; Alexey V Dobrydnev; Ivan S Kondratov; Yuriy S Moroz; Oleksandr O Grygorenko
Journal:  J Mol Struct       Date:  2020-05-10       Impact factor: 3.196

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.